The North America NGS Automation Market is expected to reach $776.1 million by 2030, at a CAGR of 14% during the forecast period 2023–2030. Next-generation Sequencing (NGS) is a genome sequencing technology usually used for research purposes and applied in clinical diagnostics. NGS determines the order of nucleotides in the entire genomes or targeted regions of DNA or RNA. It is used for various clinical applications such as disease diagnosis, prognosis, therapeutic decision, and follow-up of patients. Also, its massive parallel sequencing capacity offers new opportunities for personalized or precision medicine. The process of NGS includes processes like sample pre-processing, library preparation, sequencing, and bioinformatics. Library preparation plays a crucial role in NGS workflow, but it is still time-consuming and repetitive despite the ongoing technical advances in high-throughput sequencing. Library preparation consists of numerous, repetitive steps wherein samples are required to be pipetted in small volumes with high precision, making it highly prone to human error and compromising the entire NGS process. This has increased the demand for NGS automation. The North America NGS automation market is driven by the increasing prevalence of cancer cases, rising demand for NGS automation in laboratories, growing demand for optimized & streamlined workflows, and increasing pharmaceutical R&D investments & healthcare expenditures. Furthermore, the rising application of NGS technology and collaborations between vendors to develop library preparation protocols are expected to offer immense growth opportunities for market expansion. However, the high cost of automation workstations is expected to restrain the growth of this market to some extent. In addition, regulatory & standardized concerns associated with diagnostic testing and lack of training of laboratory personnel for the use of NGS automation software are the major challenges to the market’s growth.